


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**


1. (Currently amended) A compound represented by the formula



wherein Ring A represents an optionally substituted pyridine ring, X represents an electron-attracting group, Y represents an optionally substituted divalent C<sub>1-6</sub> chained hydrocarbon group selected from the group consisting of a C<sub>1-6</sub> alkylene group, a C<sub>2-6</sub> alkenylene group, and a C<sub>2-6</sub> alkynylene group -CH=CH- or -(CH<sub>2</sub>)<sub>2</sub>, R<sup>1</sup> represents (1) a C<sub>5-7</sub> cycloalkyl group optionally fused with a benzene ring, (2) a C<sub>7-19</sub> aralkyl group, (3) a 5- or 6-membered heterocyclic ring-C<sub>1-4</sub> alkyl group or (4) a C<sub>6-14</sub> aryloxy-C<sub>1-4</sub> alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C<sub>1-4</sub> alkyl group, a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group and a C<sub>1-4</sub> alkoxy group an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group, and R<sup>2</sup> and R<sup>3</sup> each independently represent a hydrogen atom, an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group a C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>6-14</sub>

aryl and C<sub>7-19</sub> aralkyl or an optionally substituted heterocyclic group selected from the group consisting of a 5- to 14-membered (mono- to tri-cyclic) heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom; tetrahydropyran, pyran and pyridyl, or R<sup>2</sup> and R<sup>3</sup> may form an optionally substituted ring together with an adjacent nitrogen atom, or a salt thereof.

2. (Original) The compound according to claim 1 which is a compound represented by the formula



wherein Ring A'' represents a pyridine ring which may have 1 to 3 substituents selected from a C<sub>1-4</sub> alkyl group and a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group and other symbols are as defined in claim 1, or a salt thereof.

3. (Original) The compound according to claim 1, wherein X is a nitrile group.

4. (Canceled).

5. (Canceled).

6. **(Currently amended)** The compound according to claim 1, wherein one of R<sup>2</sup> and R<sup>3</sup> is a hydrogen atom or a C<sub>1-4</sub> alkyl group, and the other is a 5- or 6-membered heterocyclic group, a C<sub>6-14</sub> aryl group, a C<sub>7-19</sub> aralkyl group, a C<sub>3-10</sub> cycloalkyl group, a tetrahydropyranyl, pyranyl and pyridyl 5- or 6-membered heterocyclic ring-C<sub>1-4</sub> alkyl group or C<sub>1-6</sub> alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C<sub>1-4</sub> alkyl group, a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group, a C<sub>1-4</sub> alkoxy group, a C<sub>1-4</sub> alkoxy-carbonyl group, a cyano group, a C<sub>1-4</sub> alkyl-carbonylamino group and a hydroxy group; or R<sup>2</sup> and R<sup>3</sup>, together with an adjacent nitrogen atom, form a 5- or 6-membered nitrogen-containing heterocyclic ring optionally containing 1 to 3 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to carbon atoms and one nitrogen atom, in which the nitrogen-containing heterocyclic ring may have 1 to 4 substituents selected from a halogen atom, a C<sub>1-4</sub> alkyl group, a mono-, di- or tri-halogeno-C<sub>1-4</sub> alkyl group, a C<sub>1-4</sub> alkoxy group and a C<sub>1-4</sub> alkoxy-carbonyl group.

7. **(Original)** (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,  
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,  
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,  
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,  
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-

pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. **(Canceled).**

9. **(Previously presented)** A medicine comprising the compound according to  
claim 1.

10. **(Original)** The medicine according to claim 9 which is a vanilloid receptor  
agonist.

11. **(Original)** The vanilloid receptor agonist according to claim 10 which is for local  
administration.

12. **(Currently amended)** The vanilloid receptor agonist according to claim 10  
which is an agent for preventing and/or treating overactive bladder.

13. **(Original)** The vanilloid receptor agonist according to claim 10 which is an  
analgesic.

14. **(Currently amended)** A method of treating overactive bladder, comprising  
administering to a mammal in need an effective amount of the compound according to claim 1-  
or  
a prodrug thereof.

15. **(Previously presented)** An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1.

16. **(Canceled).**

17. **(Canceled).**